文献速递系统性红斑狼疮

新型S1P1受体调节剂cenerimod在系统性红斑狼疮中的临床前到临床转化研究

Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus.
PubMed 文献 · RMD Open · 2020-01-01

该研究在MRL/lpr狼疮小鼠模型中评估cenerimod对淋巴细胞、器官病理、炎症和生存的影响,并在健康受试者和SLE患者中检测cenerimod诱导的S1P1受体内化;12周2期临床试验(NCT-02472795)显示SLE患者接受cenerimod治疗后血淋巴细胞、抗体分泌细胞(ASC)和血浆IFN-α呈剂量依赖性降低。

要点

  • cenerimod在MRL/lpr小鼠中减少血淋巴细胞、组织免疫浸润、蛋白尿和炎症,提高生存率。
  • 在SLE患者淋巴细胞中S1P1受体仍保持功能,cenerimod可有效诱导受体内化。
  • 12周cenerimod治疗使SLE患者血淋巴细胞、ASC和血浆IFN-α剂量依赖性降低。

核心结论

  • cenerimod在SLE小鼠模型中显著改善全身及器官特异性病理和炎症,并在SLE患者中降低血淋巴细胞、ASC和IFN相关生物标志物。

研究设计与样本

  • 临床前研究在MRL/lpr狼疮小鼠模型中评估cenerimod对淋巴细胞、器官病理、炎症和生存的影响,并检测健康受试者和SLE患者淋巴细胞中cenerimod诱导的S1P1受体内化。
  • 临床研究为12周2期试验(NCT-02472795),SLE患者接受多剂量cenerimod或安慰剂治疗,表征淋巴细胞亚群和炎症生物标志物。

主要发现

  • 在MRL/lpr小鼠中,cenerimod治疗降低血淋巴细胞,减少组织免疫浸润,减轻组织病理、蛋白尿和炎症,并提高生存率。
  • cenerimod在健康受试者和SLE患者淋巴细胞中均能强效诱导S1P1受体内化。
  • SLE患者接受12周cenerimod治疗后,血淋巴细胞、抗体分泌细胞(ASC)和血浆IFN-α呈剂量依赖性降低。

临床怎么用

  • cenerimod通过调节S1P1受体减少血淋巴细胞和ASC,降低IFN相关生物标志物,可能为SLE提供靶向淋巴细胞和干扰素通路的治疗策略。
  • SLE患者背景用药下S1P1受体仍保持功能,支持cenerimod在联合治疗背景下的进一步研究。

局限性

  • 临床数据来自12周2期研究,长期疗效和安全性尚待正在进行的长期临床研究(CARE;NCT-03742037)进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES:: SLE is an autoimmune disease characterised by aberrant lymphocyte activation and autoantibody production. This study provides an in-depth preclinical and clinical characterisation of the treatment effect of cenerimod, a sphingosine-1-phosphate receptor type 1 (S1P1) modulator, in SLE. METHODS:: Cenerimod effect on lymphocyte numbers, organ pathology, inflammation, and survival was evaluated in the MRL/lpr lupus mouse model. Lymphocytes from healthy subjects and patients with SLE were assessed for cenerimod-induced S1P1 receptor internalisation. Lymphocyte subsets and inflammatory biomarkers were characterised in a 12-week phase 2 clinical study (NCT-02472795), where patients with SLE were treated with multiple doses of cenerimod or placebo. RESULTS:: In MRL/lpr mice treated with cenerimod, blood lymphocytes were reduced, leading to reduced immune infiltrates into tissue, and decreased tissue pathology, proteinuria, and inflammation, resulting in increased survival. Cenerimod was potent and efficacious in inducing S1P1 receptor internalisation in lymphocytes in both healthy subjects and patients with SLE. In patients with SLE, 12-week cenerimod treatment resulted in a dose-dependent reduction of blood lymphocytes, antibody-secreting cells (ASC), and plasma IFN-α. CONCLUSION:: Cenerimod significantly ameliorated systemic and organ-specific pathology and inflammation in a mouse model of SLE. In lymphocytes from patients with SLE, the S1P1 receptor remained functional despite concomitant background medication. The preclinical lymphocyte reduction translated to patients with SLE and resulted in the normalisation of ASC and the reduction of IFN-associated biomarkers. The efficacy and safety of cenerimod is being further investigated in a long-term clinical study in patients with SLE (CARE; NCT-03742037).

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Strasser DS, Froidevaux S, Sippel V, et al. Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. RMD Open. 2020. PMID: 32917831. doi:10.1136/rmdopen-2020-001261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。